Rani Therapeutics Holdings, Inc.
NASDAQ:RANIBiotechnology
-$0.04 today
- Market cap
- $52.19M
- Beta
- 0.76
- P/E (TTM)
- -4.6
- EPS (TTM)
- -$0.16
Volume 0.23M
Average 1.15M
Fair Value & DCF
Compare our fair value with your own assumptions
Intrinsic Alpha selects a valuation method suited to the business. Use the calculator below to build an independent scenario with your preferred cash-flow basis.
Rani Therapeutics Holdings, Inc.
NASDAQ:RANI
Intrinsic Alpha fair value
Locked
Current Price
$0.80
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Build your own valuation
Test an independent scenario and compare it with Intrinsic Alpha's estimate.
Sign in to use the DCF calculator
Free accounts get 5 valuations per week. Upgrade for more.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | N/A | +94.7% (5yr)2 analysts |
| Net Income | N/A | N/A | N/A | N/A2 analysts |
| EBIT | N/A | N/A | N/A | N/A2 analysts |
Analysis
Forward estimates point to Revenue at +94.7% (5yr), giving you a quick read on expected growth from here.
Estimates & History
Historical data and analyst estimates. Solid bars are actuals; dashed-border bars are future estimates.
Competitor Valuations
Peer stocks ranked by intrinsic value status
| Company | Market Cap | Price | Valuation | P/E | 1Y Return |
|---|---|---|---|---|---|
Molecular Partners AG NASDAQ:MOLN | $146.67M | $3.91 | Not rated | -2.0 | -38.90% |
Innate Pharma S.A. NASDAQ:IPHA | $146.49M | $1.56 | Not rated | -3.0 | -47.49% |
Tonix Pharmaceuticals Holding Corp. NASDAQ:TNXP | $142.03M | $8.91 | Not rated | -1.1 | -83.13% |
Corbus Pharmaceuticals Holdings, Inc. NASDAQ:CRBP | $113.58M | $6.13 | Not rated | -1.3 | -79.40% |
Milestone Pharmaceuticals Inc. NASDAQ:MIST | $100.81M | $0.81 | Not rated | -2.5 | -80.24% |
Cardiff Oncology, Inc. NASDAQ:CRDF | $86.32M | $1.12 | Not rated | -1.8 | -55.37% |
Elicio Therapeutics, Inc. NASDAQ:ELTX | $36.61M | $1.92 | Not rated | -1.7 | -66.67% |
Sangamo Therapeutics, Inc. NASDAQ:SGMO | $30.66M | $0.07 | Not rated | -0.5 | -55.37% |
Continue the stock analysis
Jump to another research area for this company.